Logo

NVST

Envista Holdings Corp

NVST

Envista Holdings Corp • NYSE
$20.90 ▼ -0.43% (-0.09)
Market Cap $3.44 B
52w High $22.68
52w Low $14.22
Dividend Yield 0%
P/E 232.22
Volume 555.12K
Outstanding Shares 164.43M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $669.9M ▼ $312.7M ▼ $-30.3M ▼ -4.523% ▼ $-0.18 ▼ $96.7M ▲
Q2-2025 $682.1M ▲ $323.9M ▲ $26.4M ▲ 3.87% ▲ $0.16 ▲ $80.6M ▲
Q1-2025 $616.9M ▼ $298.9M ▼ $18M ▲ 2.918% ▲ $0.1 ▲ $77.2M ▼
Q4-2024 $652.9M ▲ $327.2M ▲ $1.2M ▼ 0.184% ▼ $0.007 ▼ $87.4M ▲
Q3-2024 $601M $296.5M $8.2M 1.364% $0.048 $51.7M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.134B ▲ $5.643B ▼ $2.554B ▲ $3.088B ▼
Q2-2025 $1.111B ▲ $5.664B ▲ $2.525B ▲ $3.139B ▲
Q1-2025 $1.077B ▲ $5.466B ▲ $2.43B ▲ $3.036B ▲
Q4-2024 $1.069B ▲ $5.351B ▼ $2.416B ▼ $2.935B ▼
Q3-2024 $991.3M $5.511B $2.438B $3.072B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-30.3M ▼ $78.7M ▼ $-9.7M ▲ $-41.7M ▲ $23.3M ▼ $67.9M ▼
Q2-2025 $26.4M ▲ $88.7M ▲ $-17.1M ▼ $-86.4M ▼ $33.3M ▲ $76.4M ▲
Q1-2025 $18M ▲ $300K ▼ $-8.8M ▼ $-17.6M ▼ $8.2M ▼ $-5.6M ▼
Q4-2024 $1.2M ▼ $132.4M ▲ $-7.4M ▲ $-900K ▲ $77.8M ▲ $123.8M ▲
Q3-2024 $8.2M $70.7M $-30.6M $-100.5M $-44.9M $63.3M

Revenue by Products

Product Q3-2023Q4-2023Q1-2024Q4-2024
Equipment and Consumables
Equipment and Consumables
 $230.00M ▲$450.00M ▲$210.00M ▼$680.00M ▲
Specialty Products and Technologies
Specialty Products and Technologies
 $400.00M ▲$830.00M ▲$410.00M ▼$1.21Bn ▲

Five-Year Company Overview

Income Statement

Income Statement Envista’s sales have been fairly steady over the last few years, rising from the pandemic period and then leveling off rather than continuing to grow strongly. Profitability tells a different story: the company moved from healthy profits a couple of years ago to a small loss, and most recently to a sizable loss. That recent swing into a deep loss appears driven more by margin pressure and likely one‑time charges than by a collapse in demand. Underlying operating performance has weakened, but not in a way that suggests the core business has disappeared – it looks more like a business under earnings pressure that may be restructuring or resetting expectations.

Balance Sheet

Balance Sheet The balance sheet shows a company with a solid asset base and a meaningful, but not excessive, level of debt. Debt has generally edged down from earlier years, while cash on hand has ticked up in the most recent year, which helps liquidity. Shareholders’ equity had been building over time, but the recent large loss has clearly eroded that cushion. Overall, the financial foundation still looks serviceable, but the hit to equity underlines the need to stabilize profits so the balance sheet does not gradually weaken from here.

Cash Flow

Cash Flow Despite the recent accounting loss, Envista continues to generate positive cash from its day‑to‑day operations, which is an important strength. Free cash flow has been consistently positive, though not especially large, suggesting the business can fund its own investments without heavy reliance on borrowing. Capital spending is relatively modest and steady, which limits cash outflows but also means growth investments need to be highly targeted. The contrast between negative earnings and positive cash flow hints at non‑cash charges or timing effects that depress reported profit more than actual cash generation.

Competitive Edge

Competitive Edge Envista holds a strong position in the dental market with a broad portfolio that covers most of a dentist’s needs, from imaging and diagnostics to implants, orthodontics, and everyday consumables. Its brands, such as Nobel Biocare, Ormco, Kerr, and DEXIS, are well‑known and give the company reach across both premium and mainstream segments. The firm’s global footprint and large installed base in clinics provide a structural advantage and make it harder for smaller rivals to displace it. At the same time, it operates in intensely competitive niches, especially clear aligners and digital imaging, where large, well‑funded competitors push pricing and innovation pressure.

Innovation and R&D

Innovation and R&D Envista is heavily focused on digital dentistry, using advanced imaging, software, and AI to create smoother workflows for dentists and orthodontists. Products like DEXIS imaging systems, Spark clear aligners, and Nobel Biocare implant platforms show a clear tilt toward higher‑technology, higher‑value segments. The company is working to link hardware and software into integrated ecosystems, which can deepen customer loyalty and raise switching costs. It also uses targeted acquisitions to add new technologies and capabilities, though success depends on its ability to integrate these offerings and keep pace with rapid changes in digital and AI‑driven dental care.

Summary

Envista appears to be a fundamentally solid dental technology company going through a more difficult earnings phase. Revenues are stable rather than fast‑growing, while profits have deteriorated, culminating in a notable recent loss that weighs on shareholder equity. On the positive side, cash generation remains positive, debt is manageable, and the company retains strong brands, deep customer relationships, and a clear strategic focus on digital dentistry and orthodontics. The key questions looking ahead are whether Envista can translate its innovation pipeline and operational system into renewed margin strength and growth, and how well it can defend and expand its position in highly competitive, fast‑moving segments such as clear aligners, implants, and AI‑driven imaging.

NEWS

November 25, 2025 · 4:20 PM UTC

Envista Announces Participation in 8th Annual Evercore Healthcare Conference

Read more

October 29, 2025 · 8:28 PM UTC

Envista Reports Third Quarter 2025 Results

Read more

October 29, 2025 · 4:15 PM UTC

Envista Announces Release of 2024 Sustainability Report

Read more

September 30, 2025 · 4:15 PM UTC

Envista Schedules Third Quarter 2025 Earnings Call

Read more